Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Mazdutide

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

Innovent · Phase 1/2 · Active, not recruiting · Enrollment 98

NCT07000955

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
IBI362n/rn/rn/rn/r
Placebon/rn/rn/rn/r
Tirzepatiden/rn/rn/rn/r

Not shown

  • IBI362: endpoint not reported
  • Placebo: endpoint not reported
  • Tirzepatide: endpoint not reported